E. Ohman J or Asset Management AB Sells 337,210 Shares of Gilead Sciences, Inc. $GILD

E. Ohman J or Asset Management AB lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 88.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 44,792 shares of the biopharmaceutical company’s stock after selling 337,210 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $5,659,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Paulson Wealth Management Inc. boosted its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 67 shares during the period. Essex Financial Services Inc. raised its stake in Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. lifted its holdings in Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the last quarter. Alpha Cubed Investments LLC lifted its holdings in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its position in Gilead Sciences by 1.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.1%

NASDAQ GILD opened at $133.06 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1-year low of $108.46 and a 1-year high of $157.29. The company has a 50 day moving average of $129.45 and a 200-day moving average of $136.34. The company has a market cap of $165.20 billion, a price-to-earnings ratio of -49.84 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the business posted $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.5 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Wall Street Analysts Forecast Growth

Several research firms have commented on GILD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Rothschild & Co Redburn lowered their price target on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 82,000 shares of company stock valued at $10,641,790. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.